Combination of Novocure Optune with Temozolomide demonstrates five-year survival
Novocure announced today results from its phase 3 pivotal EF-14 trial adding Optune to temozolomide for the treatment of newly diagnosed glioblastoma, or GBM, including results from health-related quality of life analyses, were presented at the American Society for Radiation Oncology's 2017 Annual Meeting in San Diego. Novocure's EF-14 phase 3 pivotal trial demonstrated "unprecedented" five-year survival results in newly diagnosed GBM. Patients treated with Optune in combination with temozolomide experienced a significant extension of overall survival without added toxicity compared to patients treated with temozolomide alone. The data also showed that Optune-treated patients were able to maintain quality of life for longer compared to patients treated with temozolomide alone. The EF-14 data showed median overall survival was extended by nearly five months for patients who received Optune in combination with temozolomide versus patients who received temozolomide alone. When measured annually for five consecutive years, patients treated with Optune in combination with temozolomide maintained superior rates of survival in newly diagnosed GBM versus patients treated with temozolomide alone. The five-year survival rate was 13% for patients treated with Optune together with temozolomide versus five percent for patients treated with temozolomide alone. The EF-14 data also showed that Optune with temozolomide did not negatively impact health-related quality of life, except for itchy skin. The combination treatment of Optune with temozolomide improved deterioration-free survival of several predefined health-related quality of life scales, compared to treatment with temozolomide alone.